文献速递新药、器械与细胞基因治疗研发基础与转化研究

非酒精性脂肪性肝炎药物研发的挑战与机遇

Challenges and opportunities in NASH drug development.
PubMed 文献 · Nat Med · 2023-03-09

非酒精性脂肪性肝病(NAFLD)及更严重的非酒精性脂肪性肝炎(NASH)全球流行且缺乏获批药物,肝活检组织病理学评估作为条件性批准的主要终点存在显著变异性,导致临床试验筛选失败率极高。本综述描述NAFLD-NASH药物研发的挑战及潜在缓解策略,并指出非侵入性检测需进一步数据以获监管认可作为3期试验组织学终点的替代。

要点

  • NAFLD-NASH全球流行且无获批药物,肝活检组织病理学评估是条件性批准的主要终点。
  • 肝活检组织病理学评估变异性大,导致临床试验筛选失败率极高。
  • 非侵入性检测需进一步数据以获监管认可作为3期试验组织学终点的替代。

核心结论

  • NAFLD-NASH药物研发面临肝活检组织病理学评估变异性大等挑战,需潜在缓解策略推动领域进展。
  • 非侵入性检测需进一步数据以确保获监管认可作为3期试验组织学终点的替代。

研究设计与样本

  • 综述,描述NAFLD-NASH药物研发的挑战与潜在缓解策略。

主要发现

  • 肝活检组织病理学评估存在显著变异性,导致临床试验筛选失败率极高。
  • 过去数十年已开发多种非侵入性检测与肝组织学及结局相关,用于无创评估疾病严重程度和纵向变化。
  • 非侵入性检测需进一步数据以确保获监管认可作为3期试验组织学终点的替代。

局限性

  • 原文未报告局限性

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

Nonalcoholic fatty liver disease (NAFLD) and its more severe form, nonalcoholic steatohepatitis (NASH), represent a growing worldwide epidemic and a high unmet medical need, as no licensed drugs have been approved thus far. Currently, histopathological assessment of liver biopsies is mandatory as a primary endpoint for conditional drug approval. This requirement represents one of the main challenges in the field, as there is substantial variability in this invasive histopathological assessment, which leads to dramatically high screen-failure rates in clinical trials. Over the past decades, several non-invasive tests have been developed to correlate with liver histology and, eventually, outcomes to assess disease severity and longitudinal changes non-invasively. However, further data are needed to ensure their endorsement by regulatory authorities as alternatives to histological endpoints in phase 3 trials. This Review describes the challenges of drug development in NAFLD-NASH trials and potential mitigating strategies to move the field forward.

来源:Nat Med,查看原文。版权归原作者所有。

引用

  1. Harrison SA, Allen AM, Dubourg J, et al. Challenges and opportunities in NASH drug development. Nat Med. 2023. PMID: 36894650. doi:10.1038/s41591-023-02242-6

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。